Kempharm. Such as, susceptibility to abuse, bioavailability and safety.
What’s new on Kempharm.com: Check updates and related news right now. Unfortunately, we cannot detect RSS feed on this website, but you may observe related news or Kempharm.com popular pages instead. It is generally safe for browsing, so you may click any item to proceed to the site.
News, stories and media buzz related to Kempharm
-
KemPharm, Inc. Reports Q3 2015 Resultsvia
military-technologies
Recent Clinical Development Highlights:Completed Human Abuse Liability Program for KP201/APAP, KemPharm's prodrug of hydrocodone (KP201), formulated in combination with acetaminophen (APAP)Reported positive results from second intranasal human abuse...
-
Several controversies have taken the air out of drug and biotech stocks, which performed quite well until midsummer. Among the injured players are generic drug makers, which landed hard after a high-flying period. But Oppenheimer & Co.’s Rohit Vanjani...
-
KemPharm Announces Licensing Agreement with Acura Pharmaceuticals for Aversion(R) Abuse-Deterrent Technologyvia
egyptmarketgateway
CORALVILLE, IA and PALATINE, IL —(Marketwired – October 18, 2016) – KemPharm, Inc. (NASDAQ: KMPH), a clinical–stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, and Acura Pharmaceuticals, Inc. (NASDAQ...
-
KemPharm, Inc. to Present at Canaccord Genuity 35th Annual Growth Conferencevia
virtual.tdprofiti
CORALVILLE, Iowa, Aug. 4, 2015 (GLOBE NEWSWIRE) — KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced that Travis C. Mickle, Ph.D., President...
-
Supplement to May–June 2015 Issue: CNS Summit 2014 Abstracts of Poster Presentationsvia
innovationscns
Innov Clin Neurosci. 2015;12(5–6 Suppl B):3–19 Click here to access the e-Edition, a digital replica of the printed version. CNS Drug Compounds/Therapies/Devices Long-acting injectable antipsychotics (LAIs) in outpatient treatment of DMS-IV-R schizophrenia...
You may also like
SOCRATES Journal is an international, refereed, and indexed scholarly publication focused on public policy, administration, and ph...
ALECENSA® (alectinib) and Information...
Find information for patients about treatment with ALECENSA® (alectinib). See full safety for more information.
Kempharm.com popular pages
-
KemPharm is engaged in the discovery and development of proprietary NME prodrugs that improve one or more of the attributes of approved drugs.
-
30-Year Investment Banking Veteran Joins KemPharm to Strengthen its Business & Financial Operations North Liberty, IA – July 15, 2013 – KemPharm, Inc., a clinical stage biopharmaceutical company fo...
-
About KemPharm KemPharm is engaged in the discovery and development of proprietary prodrugs that improve one or more of the attributes of approved drugs, such as susceptibility to abuse, bioavailab...
Some worthy website to observe next
Website parameters
-
20 years
Domain age
-
N/A
Visit duration
-
N/A
Daily visitors
-
N/A
Bounce rate
